Portfolio
LSP 7
Investments range between EUR 30 million and EUR 60 million
LSP 7 seeks to invest in early-to-late-stage life sciences companies, developing novel and ground-breaking new medicines and technologies that provide solutions to unmet medical needs. LSP 7’s geographical focus is primarily Europe and occasionally the US.
LSP Advisory B.V.
Johannes Vermeerplein 9
1071 DV Amsterdam, the Netherlands
Company Registration Number: 34296447
LSP Advisory B.V. is an alternative investment fund manager authorized and regulated in accordance with laws of the Netherlands.
Fast facts
- StatusActive
- Launch2021
- SizeEUR 1 bn
- SFDR classificationArt. 8
Investment advisory committee
- ChairpersonProf. dr A. Pijpers
- CompanySectorCountryEntryExit
- EvommuneHealthcareUnited States2021
- Oculis Holding AGHealthcareSwitzerland2022
- Egle TherapeuticsHealthcareFrance2021
- HotSpot TherapeuticsHealthcareUnited States2021
- Ariceum TherapeuticsHealthcareGermany2021
- Agomab TherapeuticsHealthcareBelgium2023
- Shinobi TherapeuticsHealthcareUnited States2023
- MinervaXHealthcareDenmark2023
- TubulisHealthcareGermany2024
- AvidicureHealthcareNetherlands2024